🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million new cases each year. Notably increased rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Global Access

Based on data released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which combines a dual-drug approach. The study enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians on the front lines have shared optimism. Having a easy-to-administer therapy like this is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to lessen the impact of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.